{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:04:44Z","timestamp":1792501484404,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["14977"],"award-info":[{"award-number":["14977"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["009889"],"award-info":[{"award-number":["009889"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23-NS11416"],"award-info":[{"award-number":["K23-NS11416"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The pathological hallmark of neurodegenerative diseases is the formation of toxic oligomers by proteins such as alpha-synuclein (aSyn) or microtubule-associated protein tau (Tau). Consequently, such oligomers are promising biomarker candidates for diagnostics as well as drug development. However, measuring oligomers and other aggregates in human biofluids is still challenging as extreme sensitivity and specificity are required. We previously developed surface-based fluorescence intensity distribution analysis (sFIDA) featuring single-particle sensitivity and absolute specificity for aggregates. In this work, we measured aSyn and Tau aggregate concentrations of 237 cerebrospinal fluid (CSF) samples from five cohorts: Parkinson\u2019s disease (PD), dementia with Lewy bodies (DLB), Alzheimer\u2019s disease (AD), progressive supranuclear palsy (PSP), and a neurologically-normal control group. aSyn aggregate concentration discriminates PD and DLB patients from normal controls (sensitivity 73%, specificity 65%, area under the receiver operating curve (AUC) 0.68). Tau aggregates were significantly elevated in PSP patients compared to all other groups (sensitivity 87%, specificity 70%, AUC 0.76). Further, we found a tight correlation between aSyn and Tau aggregate titers among all patient cohorts (Pearson coefficient of correlation <jats:italic>r<\/jats:italic>\u2009=\u20090.81). Our results demonstrate that aSyn and Tau aggregate concentrations measured by sFIDA differentiate neurodegenerative disease diagnostic groups. Moreover, sFIDA-based Tau aggregate measurements might be particularly useful in distinguishing PSP from other parkinsonisms. Finally, our findings suggest that sFIDA can improve pre-clinical and clinical studies by identifying those individuals that will most likely respond to compounds designed to eliminate specific oligomers or to prevent their formation.<\/jats:p>","DOI":"10.1038\/s41531-022-00330-x","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T10:06:52Z","timestamp":1654164412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Quantitative detection of \u03b1-Synuclein and Tau oligomers and other aggregates by digital single particle counting"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-9224","authenticated-orcid":false,"given":"Lara","family":"Bl\u00f6meke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Pils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Kraemer-Schulien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dybala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-3557","authenticated-orcid":false,"given":"Anja","family":"Schaffrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kulawik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8815-0684","authenticated-orcid":false,"given":"Fabian","family":"Rehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneliese","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9261-3124","authenticated-orcid":false,"given":"Volker","family":"Nischwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Tropea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Bujnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcltekin","family":"Tamg\u00fcney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Q.","family":"Trojanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bannach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen-Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-7366","authenticated-orcid":false,"given":"Dieter","family":"Willbold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"330_CR1","doi-asserted-by":"publisher","unstructured":"Dickson, D. W. Parkinson\u2019s disease and parkinsonism: neuropathology. Cold Spring Harb. Perspect Med. 2, https:\/\/doi.org\/10.1101\/cshperspect.a009258 (2012).","DOI":"10.1101\/cshperspect.a009258"},{"key":"330_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0835-5","volume":"18","author":"C Foguem","year":"2018","unstructured":"Foguem, C. & Manckoundia, P. Lewy Body Disease: Clinical and Pathological \u201cOverlap Syndrome\u201d Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr. Neurol. Neurosci. Rep. 18, 24 (2018).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"330_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101\u2013112 (2007).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"330_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","volume":"134","author":"N Bengoa-Vergniory","year":"2017","unstructured":"Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R. & Alegre-Abarrategui, J. Alpha-synuclein oligomers: A new hope. Acta Neuropathol. 134, 819\u2013838 (2017).","journal-title":"Acta Neuropathol."},{"key":"330_CR5","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.1073\/pnas.1713129115","volume":"115","author":"I Prots","year":"2018","unstructured":"Prots, I. et al. alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc. Natl Acad. Sci. USA 115, 7813\u20137818 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR6","doi-asserted-by":"publisher","unstructured":"Willbold, D. & Kutzsche, J. Do we need anti-prion compounds to treat Alzheimer\u2019s Disease? Molecules 24, https:\/\/doi.org\/10.3390\/molecules24122237 (2019).","DOI":"10.3390\/molecules24122237"},{"key":"330_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28611","author":"NK Majbour","year":"2021","unstructured":"Majbour, N. K. et al. Cerebrospinal alpha-Synuclein oligomers reflect disease motor severity in DeNoPa longitudinal cohort. Mov. Disord. https:\/\/doi.org\/10.1002\/mds.28611 (2021).","journal-title":"Mov. Disord."},{"key":"330_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","volume":"11","author":"NK Majbour","year":"2016","unstructured":"Majbour, N. K. et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease. Mol. Neurodegener. 11, 7 (2016).","journal-title":"Mol. Neurodegener."},{"key":"330_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/acn3.382","volume":"4","author":"U Sengupta","year":"2017","unstructured":"Sengupta, U. et al. Tau oligomers in cerebrospinal fluid in Alzheimer\u2019s disease. Ann. Clin. Transl. Neurol. 4, 226\u2013235 (2017).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"330_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41570-021-00254-9","volume":"5","author":"K Kulenkampff","year":"2021","unstructured":"Kulenkampff, K., Wolf Perez, A.-M., Sormanni, P., Habchi, J. & Vendruscolo, M. Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nat. Rev. Chem. 5, 277\u2013294 (2021).","journal-title":"Nat. Rev. Chem."},{"key":"330_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cca.2017.01.010","volume":"466","author":"Y Herrmann","year":"2017","unstructured":"Herrmann, Y. et al. Nanoparticle standards for immuno-based quantitation of alpha-synuclein oligomers in diagnostics of Parkinson\u2019s disease and other synucleinopathies. Clin. Chim. Acta 466, 152\u2013159 (2017).","journal-title":"Clin. Chim. Acta"},{"key":"330_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam, P., Bousset, L., Melki, R. & Otzen, D. E. alpha-synuclein oligomers and fibrils: A spectrum of species, a spectrum of toxicities. J. Neurochem. 150, 522\u2013534 (2019).","journal-title":"J. Neurochem."},{"key":"330_CR13","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1021\/acs.chemrev.1c00196","volume":"121","author":"D Willbold","year":"2021","unstructured":"Willbold, D., Strodel, B., Schroder, G. F., Hoyer, W. & Heise, H. Amyloid-type protein aggregation and prion-like properties of amyloids. Chem. Rev. 121, 8285\u20138307 (2021).","journal-title":"Chem. Rev."},{"key":"330_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3233\/JAD-160253","volume":"54","author":"M H\u00fclsemann","year":"2016","unstructured":"H\u00fclsemann, M. et al. Biofunctionalized Silica nanoparticles: Standards in amyloid-beta oligomer-based diagnosis of Alzheimer\u2019s Disease. J. Alzheimers Dis. 54, 79\u201388 (2016).","journal-title":"J. Alzheimers Dis."},{"key":"330_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fnins.2016.00008","volume":"10","author":"K K\u00fchbach","year":"2016","unstructured":"K\u00fchbach, K. et al. Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay. Front Neurosci. 10, 8 (2016).","journal-title":"Front Neurosci."},{"key":"330_CR16","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1515\/CCLM.2011.702","volume":"49","author":"N Bolstad","year":"2011","unstructured":"Bolstad, N. et al. Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera. Clin. Chem. Lab Med. 49, 2001\u20132006 (2011).","journal-title":"Clin. Chem. Lab Med."},{"key":"330_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/alzrt142","volume":"4","author":"H Vanderstichele","year":"2012","unstructured":"Vanderstichele, H., Stoops, E., Vanmechelen, E. & Jeromin, A. Potential sources of interference on Abeta immunoassays in biological samples. Alzheimers Res. Ther. 4, 39 (2012).","journal-title":"Alzheimers Res. Ther."},{"key":"330_CR18","doi-asserted-by":"publisher","first-page":"e0123162","DOI":"10.1371\/journal.pone.0123162","volume":"10","author":"R Ishii","year":"2015","unstructured":"Ishii, R. et al. Decrease in plasma levels of alpha-synuclein is evident in patients with Parkinson\u2019s disease after elimination of heterophilic antibody interference. PLoS One 10, e0123162 (2015).","journal-title":"PLoS One"},{"key":"330_CR19","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3233\/JAD-2010-100609","volume":"21","author":"D Sehlin","year":"2010","unstructured":"Sehlin, D. et al. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J. Alzheimers Dis. 21, 1295\u20131301 (2010).","journal-title":"J. Alzheimers Dis."},{"key":"330_CR20","doi-asserted-by":"publisher","unstructured":"Barkovits, K. et al. Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein. Cells 9, https:\/\/doi.org\/10.3390\/cells9020370 (2020).","DOI":"10.3390\/cells9020370"},{"key":"330_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer, B. et al. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230\u2013240 (2011).","journal-title":"Lancet Neurol."},{"key":"330_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ene.14032","volume":"27","author":"MG Forland","year":"2020","unstructured":"Forland, M. G. et al. The value of cerebrospinal fluid alpha-synuclein and the tau\/alpha-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. Eur. J. Neurol. 27, 43\u201350 (2020).","journal-title":"Eur. J. Neurol."},{"key":"330_CR23","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/mds.111","volume":"33","author":"I van Steenoven","year":"2018","unstructured":"van Steenoven, I. et al. alpha-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. Mov. Disord. 33, 1724\u20131733 (2018).","journal-title":"Mov. Disord."},{"key":"330_CR24","doi-asserted-by":"publisher","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","volume":"10","author":"S Slaets","year":"2014","unstructured":"Slaets, S. et al. Increased CSF alpha-synuclein levels in Alzheimer\u2019s disease: Correlation with tau levels. Alzheimers Dement 10, S290\u2013S298 (2014).","journal-title":"Alzheimers Dement"},{"key":"330_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jamaneurol.2013.114","volume":"70","author":"R Savica","year":"2013","unstructured":"Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E. & Rocca, W. A. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 70, 859\u2013866 (2013).","journal-title":"JAMA Neurol."},{"key":"330_CR26","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner, B. et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194\u20134199 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"330_CR27","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","volume":"75","author":"T Tokuda","year":"2010","unstructured":"Tokuda, T. et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766\u20131772 (2010).","journal-title":"Neurology"},{"key":"330_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","volume":"7","author":"MJ Park","year":"2011","unstructured":"Park, M. J., Cheon, S. M., Bae, H. R., Kim, S. H. & Kim, J. W. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson\u2019s disease. J. Clin. Neurol. 7, 215\u2013222 (2011).","journal-title":"J. Clin. Neurol."},{"key":"330_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","volume":"6","author":"L Parnetti","year":"2014","unstructured":"Parnetti, L. et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson\u2019s Disease. Front. Aging Neurosci. 6, 53 (2014).","journal-title":"Front. Aging Neurosci."},{"key":"330_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12035-012-8280-y","volume":"47","author":"K Wakabayashi","year":"2013","unstructured":"Wakabayashi, K. et al. The Lewy body in Parkinson\u2019s disease and related neurodegenerative disorders. Mol. Neurobiol. 47, 495\u2013508 (2013).","journal-title":"Mol. Neurobiol."},{"key":"330_CR31","doi-asserted-by":"publisher","unstructured":"Irwin, D. J. & Hurtig, H. I. The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J. Alzheimers Dis. Parkinsonism 8, https:\/\/doi.org\/10.4172\/2161-0460.1000444 (2018).","DOI":"10.4172\/2161-0460.1000444"},{"key":"330_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton, R. L. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 10, 378\u2013384 (2000).","journal-title":"Brain Pathol."},{"key":"330_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ana.20819","volume":"59","author":"WR Galpern","year":"2006","unstructured":"Galpern, W. R. & Lang, A. E. Interface between tauopathies and synucleinopathies: A tale of two proteins. Ann. Neurol. 59, 449\u2013458 (2006).","journal-title":"Ann. Neurol."},{"key":"330_CR34","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/brain\/awy146","volume":"141","author":"JL Robinson","year":"2018","unstructured":"Robinson, J. L. et al. Neurodegenerative disease concomitant proteinopathies are prevalent, Age-related and APOE4-associated. Brain 141, 2181\u20132193 (2018).","journal-title":"Brain"},{"key":"330_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/alzrt255","volume":"6","author":"O Hansson","year":"2014","unstructured":"Hansson, O. et al. Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson\u2019s disease with dementia and dementia with Lewy bodies compared to Alzheimer\u2019s disease. Alzheimers Res. Ther. 6, 25 (2014).","journal-title":"Alzheimers Res. Ther."},{"key":"330_CR36","doi-asserted-by":"publisher","first-page":"638718","DOI":"10.3389\/fnagi.2021.638718","volume":"13","author":"IY Abdi","year":"2021","unstructured":"Abdi, I. Y. et al. Preanalytical stability of CSF Total and Oligomeric Alpha-Synuclein. Front. Aging Neurosci. 13, 638718 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"330_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/2051-5960-2-73","volume":"2","author":"JE Gerson","year":"2014","unstructured":"Gerson, J. E. et al. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol. Commun. 2, 73 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"330_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis. Lancet Neurol. 15, 673\u2013684 (2016).","journal-title":"Lancet Neurol."},{"key":"330_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp-2014-308004","volume":"86","author":"D Wagshal","year":"2015","unstructured":"Wagshal, D. et al. Divergent CSF tau alterations in two common tauopathies: Alzheimer\u2019s disease and progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry 86, 244\u2013250 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"330_CR40","doi-asserted-by":"publisher","first-page":"42751","DOI":"10.1074\/jbc.M112.380642","volume":"287","author":"CM Karch","year":"2012","unstructured":"Karch, C. M., Jeng, A. T. & Goate, A. M. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem. 287, 42751\u201342762 (2012).","journal-title":"J. Biol. Chem."},{"key":"330_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fneur.2018.00809","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang, X. et al. Tau pathology in Parkinson\u2019s Disease. Front Neurol. 9, 809 (2018).","journal-title":"Front Neurol."},{"key":"330_CR42","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin, D. J., Lee, V. M. & Trojanowski, J. Q. Parkinson\u2019s disease dementia: Convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat. Rev. Neurosci. 14, 626\u2013636 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"330_CR43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fnins.2016.00408","volume":"10","author":"M Ingelsson","year":"2016","unstructured":"Ingelsson, M. Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson\u2019s disease and other Lewy body disorders. Front. Neurosci. 10, 408 (2016).","journal-title":"Front. Neurosci."},{"key":"330_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels, T., Choi, J. G. & Selkoe, D. J. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107\u2013110 (2011).","journal-title":"Nature"},{"key":"330_CR45","doi-asserted-by":"publisher","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","volume":"287","author":"B Fauvet","year":"2012","unstructured":"Fauvet, B. et al. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287, 15345\u201315364 (2012).","journal-title":"J. Biol. Chem."},{"key":"330_CR46","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1007\/s00216-014-7831-7","volume":"406","author":"J Heroult","year":"2014","unstructured":"Heroult, J., Nischwitz, V., Bartczak, D. & Goenaga-Infante, H. The potential of asymmetric flow field-flow fractionation hyphenated to multiple detectors for the quantification and size estimation of silica nanoparticles in a food matrix. Anal. Bioanal. Chem. 406, 3919\u20133927 (2014).","journal-title":"Anal. Bioanal. Chem."},{"key":"330_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1039\/b927500b","volume":"25","author":"S Dubascoux","year":"2010","unstructured":"Dubascoux, S. et al. Field-flow fractionation and inductively coupled plasma mass spectrometer coupling: History, development and applications. J. Anal. At. Spectrom. 25, 613\u2013623 (2010).","journal-title":"J. Anal. At. Spectrom."},{"key":"330_CR48","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1039\/C8JA00037A","volume":"33","author":"B Meermann","year":"2018","unstructured":"Meermann, B. & Nischwitz, V. ICP-MS for the analysis at the nanoscale \u2013 a tutorial review. J. Anal. At. Spectrom. 33, 1432\u20131468 (2018).","journal-title":"J. Anal. At. Spectrom."},{"key":"330_CR49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1515\/hsz-2016-0153","volume":"398","author":"K Kravchenko","year":"2017","unstructured":"Kravchenko, K. et al. Analysis of anticoagulants for blood-based quantitation of amyloid beta oligomers in the sFIDA assay. Biol. Chem. 398, 465\u2013475 (2017).","journal-title":"Biol. Chem."},{"key":"330_CR50","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jalz.2013.06.003","volume":"10","author":"JB Toledo","year":"2014","unstructured":"Toledo, J. B. et al. A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's Dement 10, 477\u2013484 e471 (2014).","journal-title":"Alzheimer's Dement"},{"key":"330_CR51","doi-asserted-by":"publisher","first-page":"e1038","DOI":"10.1212\/WNL.0000000000005166","volume":"90","author":"DJ Irwin","year":"2018","unstructured":"Irwin, D. J. et al. CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology 90, e1038\u2013e1046 (2018).","journal-title":"Neurology"},{"key":"330_CR52","doi-asserted-by":"publisher","first-page":"e0147319","DOI":"10.1371\/journal.pone.0147319","volume":"11","author":"Y Berlyand","year":"2016","unstructured":"Berlyand, Y. et al. An Alzheimer\u2019s Disease-Derived Biomarker Signature Identifies Parkinson\u2019s Disease Patients with Dementia. PLoS One 11, e0147319 (2016).","journal-title":"PLoS One"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00330-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00330-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00330-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:17:53Z","timestamp":1669299473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00330-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00330-x","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"27 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Authors declare no competing non-financial interests but the following competing financial interests: DW, OB, and AK are shareholders of attyloid GmbH. All other authors declare no competing financial interests related to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}